Novel Technology for the Detection of Low Abundance Protein

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$297,344.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43MH082619-01A1
Award Id:
89356
Agency Tracking Number:
MH082619
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
CREATV MICROTECH, INC., 11609 LAKE POTOMAC DR, POTOMAC, MD, 20854
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
008723694
Principal Investigator:
CHAMEITANG
(301) 983-1650
CMTANG@CREATVMICROTECH.COM
Business Contact:
() -
cmtang@creatvmicrotech.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): We propose a novel technology for detection of low abundance protein in body fluids, with initial application to a mental health biomarker. One of the most significant challenges facing biomarker discovery is the need t o separate high and low abundance proteins for detection of the latter more easily and with precision. The proposed technology is a novel chromatography platform that utilizes unique functionalized micro-structures to capture and purify target analytes fro m clinical tissue specimens. It does not utilize conventional beads, filters or magnets. We believe that the proposed method will stand out as is a potential breakthrough in the field of sample preparation and will be applied to analysis of numerous low ab undance biomarkers. For validation of the proposed technology, this technology will be applied to the detection of neuronal biomarkers. In Phase I of this SBIR, we plan to recover human neurofilament proteins from serum. Because of their specific localizat ion in the central nervous system, the presence of neurofilament proteins outside of this compartment may indicate damage and/or disease of the central nervous system. The presence of neurofilament proteins in body fluids can serve as a sensitive indicator of central nervous system diseases, including multiple sclerosis, Parkinson's disease and HIV dementia. This Phase I SBIR will demonstrate the proof-of-principle detection of neurofilaments as the target analyte in the proposed chromatography technology a nd design an automated instrument to be constructed in Phase II. PUBLIC HEALTH RELEVANCE: We propose to develop a novel technology for detection of low abundance protein in body fluids, with initial application to a mental health biomarker called n eurofilaments. Because of their specific localization in the central nervous system, the presence of neurofilament proteins outside this compartment may indicate damage and/or disease of the central nervous system. The presence of neurofilament proteins in body fluids can serve as a sensitive indicator of central nervous system diseases, including multiple sclerosis, Parkinson's disease and HIV dementia.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government